Swalqol in Primary Hyperparathyroidism

The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03968510

Enrollment

150

Registered

2019-05-30

Start date

2018-11-01

Completion date

2020-11-01

Last updated

2021-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism

Brief summary

Swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.

Detailed description

Patients who will undergone parathyroidectomy for primary hyperparathyroidism will be included in the study. Swal-Qol and Sf-36 forms will be used for evaluation of quality of life before and 1 month after the surgery. The change in the quality of life and swallowing related quality of life will be evaluated.

Interventions

PROCEDUREparathyroidectomy

routine parathyroidectomy will be done for the treatment of adenoma

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* no diagnosis of Alzheimers disease * must be able to swallow tablets Planned operation for primary hyperparathyroidism

Exclusion criteria

* secondary or tertiary hyperparathyroidism * insulin dependent diabetes * thyroid disease

Design outcomes

Primary

Measure	Time frame	Description
Change in quality of life	6 months	Quality of life will be evaluated using short form 36

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026